Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 2
2005 2
2006 2
2007 2
2008 1
2009 3
2010 4
2011 4
2012 5
2013 1
2014 3
2015 5
2016 5
2017 8
2018 3
2019 3
2020 6
2021 3
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Squifflet P, Saad ED, Loibl S, van Mackelenbergh MT, Untch M, Rastogi P, Gianni L, Schneeweiss A, Conte P, Piccart M, Bonnefoi H, Jackisch C, Nekljudova V, Tang G, Valagussa P, Neate C, Gelber R, Poncet C, Heinzmann D, Denkert C, Geyer CE Jr, Cortes J, Guarneri V, de Azambuja E, Cameron D, Ismael G, Wolmark N, Cortazar P, Buyse M; CTNeoBC Project. Squifflet P, et al. Among authors: saad ed. J Clin Oncol. 2023 Jun 1;41(16):2988-2997. doi: 10.1200/JCO.22.02363. Epub 2023 Mar 28. J Clin Oncol. 2023. PMID: 36977286
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
van Mackelenbergh MT, Loibl S, Untch M, Buyse M, Geyer CE Jr, Gianni L, Schneeweiss A, Conte P, Piccart M, Bonnefoi H, Jackisch C, Nekljudova V, Tang G, Valagussa P, Neate C, Gelber R, Poncet C, Squifflet P, Saad ED, Heinzmann D, Denkert C, Rastogi P, Cortes J, Guarneri V, de Azambuja E, Cameron D, Ismael G, Wolmark N, Cortazar P; CTNeoBC project. van Mackelenbergh MT, et al. Among authors: saad ed. J Clin Oncol. 2023 Jun 1;41(16):2998-3008. doi: 10.1200/JCO.22.02241. Epub 2023 Apr 19. J Clin Oncol. 2023. PMID: 37075276
Precision medicine needs randomized clinical trials.
Saad ED, Paoletti X, Burzykowski T, Buyse M. Saad ED, et al. Nat Rev Clin Oncol. 2017 May;14(5):317-323. doi: 10.1038/nrclinonc.2017.8. Epub 2017 Feb 7. Nat Rev Clin Oncol. 2017. PMID: 28169302 Review.
The search for surrogate endpoints for immunotherapy trials.
Buyse M, Burzykowski T, Saad ED. Buyse M, et al. Among authors: saad ed. Ann Transl Med. 2018 Jun;6(11):231. doi: 10.21037/atm.2018.05.16. Ann Transl Med. 2018. PMID: 30023394 Free PMC article. No abstract available.
Minimization in randomized clinical trials.
Coart E, Bamps P, Quinaux E, Sturbois G, Saad ED, Burzykowski T, Buyse M. Coart E, et al. Among authors: saad ed. Stat Med. 2023 Dec 10;42(28):5285-5311. doi: 10.1002/sim.9916. Epub 2023 Oct 23. Stat Med. 2023. PMID: 37867447
Trial Design for Cancer Immunotherapy: A Methodological Toolkit.
Saad ED, Coart E, Deltuvaite-Thomas V, Garcia-Barrado L, Burzykowski T, Buyse M. Saad ED, et al. Cancers (Basel). 2023 Sep 21;15(18):4669. doi: 10.3390/cancers15184669. Cancers (Basel). 2023. PMID: 37760636 Free PMC article. Review.
Commentary on Bamat et al.
Saad ED, Buyse M. Saad ED, et al. Clin Trials. 2020 Oct;17(5):560-561. doi: 10.1177/1740774520941442. Epub 2020 Jul 15. Clin Trials. 2020. PMID: 32666828 No abstract available.
75 results